All medical procedures have a success and failure rate, and therefore there are Regenexx successes and failures. I’d like to blog on two patients this morning who are both treatment failures. One had the Regenexx-SD procedure for a torn meniscus after a very aggressive menisectomy and the other had the Regenexx-C procedure at the Cayman facility in the Cayman Islands for severe degenerative joint disease. Both are good examples that these procedures, like all medical or surgical procedures you could contemplate, have failure rates, something we’ve always been very open about.
JB is an 18 year old who had menisectomies in 2011 for sports related injuries. After some of the bilateral posterior horn of the medial meniscus was removed he felt substantially worse post surgery. His remaining meniscus then tore on both sides. When we first evaluated the patient we felt there was a good chance of helping the remaining bilateral meniscus heal due to his young age by using a Regenexx-SD procedure. Regrettably, likely due to the increased pressure on the remaining meniscus, we were unable to get one meniscus to heal but based on his recent MRI report the other meniscus did heal with the stem cell injections. However, despite this he has had no improvement in pain.
The second patient is MA, who is a 58 year old male with a 6 year history of knee pain when he was seen in 2012. The knee was severely degenerative, but had initially responded to prolotherapy by another provider and at some point was responsive to viscosupplementation (OrthoVisc, SynVisc type lubricating gel injections) and only minimally responsive to a steroid shot. Additional prolo eventually didn’t help. The patient was placed in the fair category even for the cultured procedure due other health issues such as a metabolic syndrome which we have seen impact the health of stem cells. He was given about a 40-50% chance of a treatment failure due to these issues and he has in fact not responded to the treatment. We have seen about 2/3 of patients with severe knee arthritis respond, so this gentleman is clearly in that 1/3 that doesn’t respond with at least 50% improvement.
Both of these cases demonstrate that every medical procedure, including these procedures have success and failure rates. This is why we make every attempt to discuss a candidacy with every patient we see and openly publish our registry data both on-line and when we have enough, in peer reviewed research. If you’re planning on getting a Regenexx procedure, we urge you to factor in that like every procedure you could contemplate, this procedure has a success and failure rate for all patients, regardless of their pathology.
RegenexxCayman is an independently owned and operated medical services provider operating exclusively in the Cayman Islands and is not part of or affiliated with the Centeno-Schultz Clinic or any U.S. Regenexx Network provider. The Regenexx-C procedure licensed by RegenexxCayman is not approved by the U.S. FDA for use in the United States.